🔎 Trials Near Me

홈 › 만성 림프구성 백혈병 › 펜실베이니아

펜실베이니아의 만성 림프구성 백혈병 임상 시험

만성 림프구성 백혈병 관련 연구 22개가 펜실베이니아 내 여러 지역에서 참여자를 모집하고 있습니다.

펜실베이니아의 도시

공식 연구 텍스트(영어)

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

  • Lehigh Valley Hospital-Cedar Crest, Allentown
  • Lehigh Valley Hospital - Muhlenberg, Bethlehem
  • Geisinger Medical Center, Danville
  • 외 4개
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 12. 업데이트됨 · NCT04269902

ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL

  • UPMC Hillman Cancer Center, Pittsburgh
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 12. 업데이트됨 · NCT07342478

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

  • Cancer Care Associates Of York, York
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 11. 4. 업데이트됨 · NCT06588478

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Lehigh Valley Hospital-Cedar Crest, Allentown
  • Lehigh Valley Hospital - Muhlenberg, Bethlehem
  • Geisinger Medical Center, Danville
  • 외 7개
피험자 모집 중관찰 연구건강한 지원자 환영
40세 ~ 75세 · 모든 성별 · 2026. 11. 4. 업데이트됨 · NCT05334069

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

  • Geisinger Medical Center, Danville
  • Thomas Jefferson University Hospital, Philadelphia
  • Jefferson Torresdale Hospital, Philadelphia
  • 외 1개
피험자 모집 중3상
65세 이상 · 모든 성별 · 2026. 11. 3. 업데이트됨 · NCT07321652

Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies

  • UPMC Hillman Cancer Center, Pittsburgh
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 11. 3. 업데이트됨 · NCT07520006

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

  • UPMC Hillman Cancer Center, Pittsburgh
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 11. 3. 업데이트됨 · NCT07221500

A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

  • Research Site, Philadelphia
  • Research Site, Pittsburgh
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 10. 28. 업데이트됨 · NCT06564038

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

  • Penn State Milton S Hershey Medical Center, Hershey
  • Thomas Jefferson University, Philadelphia
  • Upmc Hillman Cancer Center(Univ of Pittsburgh), Pittsburgh
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 10. 23. 업데이트됨 · NCT06943872

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

  • Penn State Hershey Medical Center, Hershey
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 10. 14. 업데이트됨 · NCT07648264

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

  • Consultants in Medical Oncology and Hematology (CMOH) ( Site 8002), Broomall
  • Cancer Care Associates Of York ( Site 0005), York
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 10. 13. 업데이트됨 · NCT06136559

Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia

  • UPMC Hillman Cancer Center, Pittsburgh
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 10. 6. 업데이트됨 · NCT07061951

A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

  • Upmc Hillman Cancer Center(Univ of Pittsburgh), Pittsburgh
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 28. 업데이트됨 · NCT07277231

A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

  • Fox Chase Cancer Center, Philadelphia
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 28. 업데이트됨 · NCT06973187

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

  • University of Pennsylvania, Abramson Cancer Center, Philadelphia
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 7. 2. 업데이트됨 · NCT05131022

A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies

  • UPMC Hillman Cancer Center, Pittsburgh
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 6. 12. 업데이트됨 · NCT07271667

A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

  • University of Pennsylvania Hospital, Philadelphia
피험자 모집 중4상
18세 이상 · 모든 성별 · 2026. 3. 2. 업데이트됨 · NCT06876649

A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

  • University of Pennsylvania Hospital, Philadelphia
피험자 모집 중4상
18세 이상 · 모든 성별 · 2026. 3. 2. 업데이트됨 · NCT06876662

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)

  • Pennsylvania Oncology Hematolo /ID# 249637, Philadelphia
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 2. 9. 업데이트됨 · NCT04895436

Two Step Haplo With Radiation Conditioning

  • Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadephia
피험자 모집 중2상
18세 이상 · 모든 성별 · 2025. 10. 30. 업데이트됨 · NCT05031897

Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia

  • AHN Cancer Institute - West Penn Hospital, Pittsburgh
피험자 모집 중2상
18세 ~ 79세 · 모든 성별 · 2025. 1. 13. 업데이트됨 · NCT05281809

ClinicalTrials.gov 출처, 2026. 11. 15. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.